On Sunday, Novartis Presented 12-month Data From The Phase 3 APPEAR-C3G Study At American Society Of Nephrology Kidney Week 2024 Showing That C3 Glomerulopathy Patients Treated With Oral Fabhalta (Iptacopan) In Addition To Supportive Care Experienced Clinically Meaningful, Sustained Results At One Year
Portfolio Pulse from Benzinga Newsdesk
Novartis presented positive 12-month data from the Phase 3 APPEAR-C3G study at the American Society of Nephrology Kidney Week 2024. The study showed that C3 glomerulopathy patients treated with oral Fabhalta (Iptacopan) experienced clinically meaningful, sustained results at one year.
October 28, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis presented positive results from a Phase 3 study for Fabhalta (Iptacopan), showing sustained benefits for C3 glomerulopathy patients over 12 months.
The positive Phase 3 study results for Fabhalta (Iptacopan) are significant as they demonstrate sustained clinical benefits, which could enhance the drug's market potential and positively impact Novartis' stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90